Annual prostate cancer incidence in the United States is close to 250 000, illustrating the unmet need for markers that contribute specificity beyond that of total PSA in order to discriminate between men with cancers likely to influence the length or quality of life and those with indolent disease or benign conditions associated with PSA elevation in blood. This evidence concerns the gene KLK3 and prostate carcinoma.